IQV — IQVIA Holdings, Inc.
Is IQV overbought or oversold? Here is the current MarketMoodz read.
IQVIA Holdings, Inc. (IQV) currently reads Oversold on the MarketMoodz overbought/oversold meter, as of November 17, 2026. The Healthcare name (Diagnostics & Research) last closed at $264.73. The rating moved from Neutral to Oversold on November 13, 2026.
- Public ratingOversold (as of November 17, 2026)
- Last close$264.73
- Last changeMoved from Neutral to Oversold on November 13, 2026
- SectorHealthcare
- IndustryDiagnostics & Research
See all oversold Healthcare stocks →
AI analysis
IQVIA is positioned to benefit from continued outsourcing of drug development and increasing demand for real‑world evidence and commercial analytics. Its scale and integrated service mix provide durable client relationships and cash flow to fund technology investment and selective M&A. Near‑term performance will be influenced by project timing, wins/losses on large contracts and macro R&D budgets. Market sentiment in the short window is measured and favors defensive large‑cap healthcare exposures, which supports relative stability. Limited social sentiment and recent macro caution add some short‑term uncertainty, but the structural demand drivers for IQVIA’s offerings remain intact.
Key factors
- Large, diversified clinical research and life‑sciences data/analytics franchise with recurring contract revenue and strong client stickiness
- Secular growth in outsourced R&D spending, real‑world evidence, and data‑driven commercial services supports sustainable top‑line expansion
- Scale and integrated service offering (CRO + commercial analytics + tech platforms) create competitive advantages versus single‑service peers
- Solid cash flow generation enabling reinvestment in technology, selective M&A, and potential shareholder returns
- Sector dynamics (pharma consolidation, specialty care growth, obesity/GLP‑1 acceleration) increase demand for end‑to‑end clinical, data and commercialization services
- Measured market tone and defensive flows into healthcare large‑caps support relative stability versus broader market drawdowns
Risks
- Client concentration and project timing: large program delays or cancellations can create near‑term revenue volatility
- Competitive pressure from other global CROs, consultancies and vertically integrated service providers compressing pricing or win rates
- Regulatory and antitrust scrutiny in healthcare could increase compliance costs or alter client behaviour
- Macroeconomic/biopharma R&D spending cyclicality — sponsor budget slowdowns would directly reduce CRO demand
- Foreign exchange exposure and integration risk from acquisitions could weigh on margins and reported results
- Limited publicly available incremental filings or social sentiment data in the near term increases short‑term information asymmetry
Latest MarketMoodz coverage
See today's live rating, score and targets
Members see the live hourly rating for IQV — the numeric AI score plus targets and entry zones — while this public page updates nightly.
Start the 14-day trialThis page is for informational purposes only and is not investment, financial, tax, or legal advice. Ratings and research outputs can be wrong, incomplete, or stale. Past performance does not guarantee future results. Always do your own research and consider consulting a qualified professional.